GENINCA
Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
| Coordinatore | Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
| Nazionalità Coordinatore | Austria [AT] |
| Sito del progetto | http://www.geninca.eu/ |
| Totale costo | 4˙033˙238 € |
| EC contributo | 2˙995˙569 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-01-01 - 2011-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Medizinische Universitaet Graz
Organization address
address: AUENBRUGGERPLATZ 2 contact info |
AT (GRAZ) | coordinator | 0.00 |
| 2 |
BIOLUTION GMBH
Organization address
address: Karl-Farkas-Gasse 22 contact info |
AT (WIEN) | participant | 0.00 |
| 3 |
CANCER RESEARCH UK
Organization address
address: ST JOHN STREET 407 ANGEL BUILDING contact info |
UK (LONDON) | participant | 0.00 |
| 4 |
IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE
Organization address
address: "Via Adamello, 16" contact info |
IT (MILAN) | participant | 0.00 |
| 5 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
| 6 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 0.00 |
| 7 |
JOHANNES GUTENBERG UNIVERSITAET MAINZ
Organization address
address: SAARSTRASSE 21 contact info |
DE (MAINZ) | participant | 0.00 |
| 8 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 0.00 |
| 9 |
ORIDIS BIOMARKERS GMBH
Organization address
address: SCHONBRUNNER STRASSE 218-A-4.04 contact info |
AT (WIEN) | participant | 0.00 |
| 10 |
ORIDIS BIOMED FORSCHUNGS-UND ENTWICKLUNGS GMBH
Organization address
address: Stiftingtalstrasse 3-5 contact info |
AT (GRAZ) | participant | 0.00 |
| 11 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 12 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 0.00 |
| 13 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 0.00 |
| 14 |
UNIVERSITATSKLINIKUM ERLANGEN
Organization address
address: Maximiliansplatz 2 contact info |
DE (ERLANGEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'GENINCA will address two tumor entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature: colorectal and liver cancer. Colorectal cancer amounts to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most common liver cancer, i.e. hepatocellular carcinoma (HCC), is among the most lethal form of cancer, and its incidence in Europe has been steadily rising over the last few decades. GENINCA represents a collaborative study of 8 academic and 3 industrial partners from 5 European countries. GENINCA will focus on exploring pre-cancerous and cancer lesions of the two aforementioned tumor entities and their respective microenvironment. As the recent identification of human colon-cancer initiating cells by one of our academic consortium members paves the way for completely new strategies for studying mechanisms of tumorigenesis, a particular focus of this grant proposal will be the detailed characterization of these cancer initiating stem cells. At present, it is still a matter of debate which genomic changes are already present in precursor lesions and whether these lesions already show genetic instability. We will therefore address the occurrence of genomic instability and explore their underlying mechanisms especially in pre-cancerous and early cancer lesions. This will be greatly facilitated by in vivo endomicroscopy approaches, sophisticated animal models and large-scale genomic and proteomic analyses. Furthermore, we will include an in-depth analysis of the corresponding microenvironment. As this represents a translational research effort, we expect to identify markers for novel therapeutic and/or preventative strategies, as well as to facilitate tumor diagnosis, prognosis, and monitoring.'